VAXIPET DHPPI+LR

Indications

• Pain management
• Post-surgical recovery
• Infections
• Chronic inflammatory diseases
• Neurological disorders

Dosage

Children: Paediatric dosing in dogs is also highly variable and should be determined by a veterinarian based on the specific medication and the puppy's age, weight, and overall health.

Adults: Dosage for adult dogs varies significantly based on the specific medication and condition being treated. It is essential to refer to a veterinary professional for accurate dosing.

Mechanism of action

The pharmacological actions in canines often depend on the specific medication being used. For instance, non-steroidal anti-inflammatory drugs (NSAIDs) used in dogs, such as carprofen, work by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), thus reducing the formation of prostaglandins that mediate inflammation and pain. Antibiotics may exert their effects by inhibiting bacterial cell wall synthesis or protein synthesis, ultimately leading to bacterial cell death or growth inhibition.

Pharmacodynamics

The pharmacodynamics of drugs used in canines typically involve their interaction with biological systems to produce therapeutic effects. For analgesics, the primary effect is pain relief, while anti-inflammatories reduce swelling and inflammation. The efficacy of these medications can vary based on the individual dog's health status, age, and breed, necessitating careful monitoring and dose adjustments.

Pharmacokinetics

Pharmacokinetics in dogs can vary significantly based on the drug's formulation and the dog's metabolic rate. Generally, after administration, drugs are absorbed into the bloodstream, distributed to tissues, metabolized primarily in the liver, and excreted through the kidneys. Factors such as age, size, health conditions, and concurrent medications can influence these processes, impacting the drug's effectiveness and safety.

Pregnancy

Safety during pregnancy has not been established. Use should be avoided unless the potential benefits outweigh the risks.

Breast-feeding

Safety during breastfeeding has not been established. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct light. Keep out of reach of children.

Dosage

Children: Refer to the BNF for Children for appropriate dosing information.

Adults: Refer to specific product guidelines and the BNF for appropriate dosing information.

Mechanism of action

The mechanism of action for a component depends on its individual pharmacological characteristics. Components may act as agonists or antagonists at specific receptors, inhibit or enhance enzyme activity, or modulate neurotransmitter levels. For example, some components may increase the availability of a neurotransmitter at synapses, thereby enhancing or inhibiting certain physiological responses.

Pharmacodynamics

Pharmacodynamics of a component involves the study of its effects on the body, including its therapeutic effects, side effects, and the relationship between drug concentration and effect. The efficacy of a component can be influenced by the presence of other ingredients in a formulation, as well as by individual patient factors such as age, weight, and genetic makeup. The therapeutic window of components can vary, necessitating careful monitoring to avoid toxicity.

Pharmacokinetics

Pharmacokinetics refers to the absorption, distribution, metabolism, and excretion (ADME) of a component. The bioavailability of a component can be affected by its formulation, route of administration, and the presence of food. Components may be metabolized in the liver or other tissues, and their elimination can occur via the kidneys or other pathways. The half-life and clearance rates of components are essential for determining dosing intervals and potential accumulation in the body.

Pregnancy

Consult a healthcare provider as safety in pregnancy varies with specific components.

Breast-feeding

Consult a healthcare provider as safety in breastfeeding varies with specific components.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Viral infections
• Bacterial infections
• Parasitic infections
• Fungal infections
• Contagious diseases like influenza, chickenpox, and tuberculosis

Dosage

Children: Refer to paediatric dosing guidelines based on the specific infectious agent and clinical context.

Adults: Refer to specific treatment guidelines based on the infectious agent and clinical context.

Mechanism of action

The mechanism of action for contagiosae can vary widely depending on the specific pathogen and the host's immune response. Generally, infectious agents invade host cells, reproduce, and cause cellular damage, leading to symptoms of disease. The immune system responds by activating various pathways, including the innate and adaptive immune responses, to eliminate the pathogen.

Pharmacodynamics

Pharmacodynamics in the context of contagiosae involves understanding how the body responds to the infectious agent and the medications used for treatment. This includes the interaction between the drug and the pathogen, the immune response elicited by the infection, and the resultant effects on the host's physiology. Medications may work by inhibiting pathogen replication, enhancing immune responses, or alleviating symptoms.

Pharmacokinetics

Pharmacokinetics for treatments related to contagiosae includes absorption, distribution, metabolism, and excretion of the drugs used. Absorption may be affected by the route of administration, with some drugs administered orally, intravenously, or topically depending on the infection's location. Distribution involves the drug's reach to tissues and fluids where the pathogen resides. Metabolism typically occurs in the liver, and excretion may primarily happen through the kidneys. These factors influence the drug's efficacy and safety.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether contagiosae is excreted in human milk. Caution should be exercised when administering to a nursing mother.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Dihydropyrimidine metabolism disorders
• Cancers with pyrimidine pathway involvement
• Potential adjunct therapy in certain chemotherapeutic regimens

Dosage

Children: Refer to specific clinical guidelines and literature for pediatric dosing information, as it is typically determined based on the child's condition and weight.

Adults: Refer to specific clinical guidelines and literature for dosing information, as dosing may vary based on the condition being treated.

Mechanism of action

DHPPi acts by inhibiting the enzyme dihydropyrimidine dehydrogenase (DPD), which is responsible for the breakdown of pyrimidine nucleotides. By blocking this enzyme, DHPPi increases the availability of these nucleotides, which can enhance nucleic acid synthesis and may have implications in both metabolic and cancer-related pathways.

Pharmacodynamics

The pharmacodynamics of DHPPi are characterized by its ability to elevate the levels of dihydropyrimidines, thereby influencing cellular proliferation and survival. This effect can lead to enhanced therapeutic responses in certain cancers and metabolic disorders where pyrimidine metabolism is disrupted. The inhibition of DPD can also alter the pharmacokinetics of other drugs metabolized by this pathway.

Pharmacokinetics

The pharmacokinetics of DHPPi, including absorption, distribution, metabolism, and excretion, are not well-documented in public databases. However, similar agents in this class typically demonstrate variable bioavailability and are subject to hepatic metabolism. The half-life may vary depending on the formulation and route of administration. Renal function may also significantly impact the clearance of the drug.

Pregnancy

The safety of DHPPi in pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether DHPPi is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Indications

• Urinary tract infections
• Respiratory tract infections
• Gastrointestinal infections
• Skin and soft tissue infections
• Bone and joint infections

Dosage

Children: Refer to the latest clinical guidelines or pediatric dosing references for specific dosing recommendations.

Adults: Refer to the latest clinical guidelines or prescribing information for specific dosing recommendations.

Mechanism of action

Enteridis works by inhibiting bacterial DNA gyrase and topoisomerase IV, enzymes that are essential for bacterial DNA replication, transcription, and repair. This inhibition leads to the disruption of DNA supercoiling, ultimately resulting in bacterial cell death.

Pharmacodynamics

The pharmacodynamics of Enteridis involves its bactericidal action, which is concentration-dependent. The drug exhibits a post-antibiotic effect, meaning that it continues to suppress bacterial growth even after plasma concentrations have fallen below the minimum inhibitory concentration (MIC). Resistance mechanisms may include mutations in the target enzymes and efflux pump activation, which can limit its effectiveness.

Pharmacokinetics

Enteridis is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-3 hours after oral administration. It has a large volume of distribution, indicating extensive tissue penetration. The drug is primarily eliminated via the kidneys, with a half-life ranging from 6-8 hours in healthy individuals. Dosage adjustments may be necessary in patients with renal impairment.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Caution is advised as it is unknown whether the drug is excreted in human milk. Consider the benefits of breastfeeding against the need for the drug.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Fever
• Mild to moderate pain
• Headache
• Muscle aches
• Arthritis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosing recommendations.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Febris primarily acts by inhibiting cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are mediators of inflammation and fever. By reducing the levels of these compounds, febris leads to decreased hypothalamic set-point, thereby lowering body temperature.

Pharmacodynamics

The pharmacodynamic effects of febris include its analgesic, antipyretic, and anti-inflammatory properties. It effectively reduces fever in response to infection or inflammation by acting on the hypothalamus. It also provides pain relief by inhibiting prostaglandin synthesis, thus alleviating symptoms associated with various conditions such as headaches, muscle aches, and arthritis.

Pharmacokinetics

Febris is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours following oral administration. It is metabolized primarily in the liver, undergoing conjugation to form inactive metabolites. The elimination half-life varies between individuals but is generally around 2-4 hours. The drug is excreted primarily through the kidneys, with a small amount eliminated in feces.

Pregnancy

Use with caution, as safety during pregnancy has not been established.

Breast-feeding

Use with caution, as safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Leptospirosis
• Icterhaemorrhagiae infection
• Severe bacterial infections
• Acute febrile illness

Dosage

Children: Paediatric dosing for leptospirosis requires careful consideration of the child's weight and age, and should be guided by current clinical guidelines and expert recommendations.

Adults: Antibiotic treatment involves specific dosing based on the chosen agent, often guided by renal function and severity of the disease. Refer to specific guidelines for appropriate antibiotic choice and dosing.

Mechanism of action

Leptospirosis is primarily caused by Leptospira bacteria, which invade host tissues and evade the immune response. The bacteria can enter the bloodstream, leading to systemic infection. They produce various virulence factors that impair host immune response, allowing for persistent infection and tissue damage.

Pharmacodynamics

The pharmacodynamics of treatments for leptospirosis, such as antibiotics, involve the inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, which ultimately leads to bacterial cell death. The effectiveness of treatment is influenced by the stage of the disease and the severity of the infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis vary by drug. Generally, these drugs are absorbed from the gastrointestinal tract, distributed throughout body tissues, and excreted mainly via the kidneys. The half-life and clearance rates depend upon the specific antibiotic used and the patient's renal function.

Pregnancy

The safety of icterohaemorrhagiae during pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known if icterohaemorrhagiae is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• HIV infection
• AIDS-related complex

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the relevant guidelines and clinical protocols for specific dosing information.

Mechanism of action

Inacavir is phosphorylated intracellularly to its active triphosphate form. This active form competes with natural deoxynucleoside triphosphates for incorporation into viral DNA, leading to chain termination during the synthesis process. This halts the replication of the virus, thereby reducing the viral load in the body.

Pharmacodynamics

Inacavir exhibits a dose-dependent inhibition of HIV-1 replication. Its efficacy is related to its ability to penetrate HIV-infected cells and its affinity for the reverse transcriptase enzyme. The drug's effect is enhanced when used in combination therapy, given that it targets a specific stage in the HIV life cycle while other drugs may target different stages.

Pharmacokinetics

Inacavir is rapidly absorbed after oral administration, with peak plasma concentrations occurring approximately 1 to 1.5 hours post-dose. It has an extensive volume of distribution and is primarily metabolized by the liver via the UDP-glucuronosyltransferase pathway. The elimination half-life is approximately 1.5 hours, and it is primarily excreted through urine as metabolites, with less than 5% of the dose excreted unchanged.

Pregnancy

Use during pregnancy only if clearly needed, as safety in pregnancy has not been established.

Breast-feeding

Caution is advised when administering to breastfeeding mothers.

Storage

Store at room temperature, away from light and moisture.

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Laryngotracheitis (croup)
• Acute upper respiratory tract infections
• Viral infections causing airway inflammation

Dosage

Children: Refer to specific pediatric guidelines for dosing based on age and weight, particularly when prescribing corticosteroids.

Adults: Refer to specific guidelines as dosing will depend on the severity of symptoms and the specific corticosteroid used.

Mechanism of action

The inflammation in laryngotracheitis is primarily mediated by the immune response to viral infection, leading to edema and narrowing of the airway. This results in increased respiratory effort and potential airway obstruction. The use of corticosteroids in treatment helps to reduce inflammation and swelling in the airway, improving airflow and alleviating symptoms.

Pharmacodynamics

Corticosteroids, such as dexamethasone, are often used in the management of laryngotracheitis due to their anti-inflammatory properties. They act by inhibiting the release of inflammatory mediators, reducing edema, and promoting the resolution of inflammation in the airway tissues. This results in improved ventilation and symptom relief.

Pharmacokinetics

Corticosteroids are well absorbed from the gastrointestinal tract when administered orally. They have a high protein binding capacity and are metabolized primarily in the liver. The elimination half-life varies depending on the specific steroid used but generally ranges from 3 to 6 hours. The onset of action can be rapid, with peak effects typically observed within hours to a few days following administration.

Pregnancy

No specific data available regarding safety in pregnancy. Consult relevant guidelines.

Breast-feeding

No specific data available regarding safety in breastfeeding. Consult relevant guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Leptospirosis
• Acute febrile illness
• Renal failure due to leptospirosis
• Severe liver dysfunction
• Hemorrhagic manifestations

Dosage

Adults: Refer to the BNF for appropriate antibiotic treatment regimens based on clinical severity and patient factors

Mechanism of action

Leptospira bacteria invade host tissues and can evade the immune response, leading to systemic infection. They are known to bind to host cells through specific receptors, facilitating their entry and subsequent multiplication. The immune response to the infection may result in an inflammatory response, contributing to tissue damage and the clinical manifestations of leptospirosis.

Pharmacodynamics

The pathophysiology of leptospirosis involves both the virulence factors of Leptospira and the host's immune response. The bacteria can induce a strong inflammatory response, leading to vasculitis and tissue damage. Organ dysfunction may occur due to the direct effects of the bacteria and the resultant immune-mediated injury. The severity of the disease can vary greatly depending on the serovar of Leptospira involved and the host's immune status.

Pharmacokinetics

Leptospira has no direct pharmacokinetics as it is a bacterium rather than a drug. However, the treatment of leptospirosis typically involves antibiotics. Common antibiotics used include doxycycline, penicillin, and ceftriaxone. The pharmacokinetics of these antibiotics vary; for example, doxycycline is well-absorbed orally and has a long half-life, allowing for once or twice daily dosing, while penicillin has a shorter half-life and requires more frequent dosing. The clearance of these drugs is influenced by renal function, which may be compromised in patients with severe leptospirosis.

Adverse effects

• Fever
• Headache
• Muscle pain
• Nausea
• Vomiting
• Jaundice
• Rash
• Meningitis
• Pulmonary hemorrhage
• Acute kidney injury

Precautions

• Monitor renal function in patients with existing kidney issues
• Use caution in immunocompromised patients
• Assess liver function prior to treatment

Pregnancy

The safety of leptospira treatment during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not well studied in breastfeeding women. Caution is advised.

Storage

Store at room temperature, away from direct sunlight. Keep out of reach of children.

Indications

• Croup
• Bronchitis
• Pneumonia
• Upper respiratory infections

Dosage

Children: Refer to clinical guidelines for supportive care and management of symptoms. No specific antiviral treatment is

Adults: Refer to clinical guidelines for supportive care and management of symptoms. No specific antiviral treatment is typically indicated.

Mechanism of action

Parainfluenza viruses attach to host cells via specific receptors, leading to viral entry and replication. The viral envelope contains glycoproteins that facilitate fusion with the host cell membrane, allowing the viral nucleocapsid to enter the cytoplasm. Once inside, the virus hijacks the host's cellular machinery to replicate its RNA genome and produce viral proteins, ultimately leading to the assembly and release of new viral particles. This process elicits an immune response, which results in inflammation and respiratory symptoms.

Pharmacodynamics

The pharmacodynamics of parainfluenza viruses primarily involves their interaction with the host immune system. Infection triggers an innate immune response characterized by the release of interferons and other cytokines, which help to control viral replication. The severity of symptoms and the clinical course of the disease can be influenced by the host's immune status, age, and underlying health conditions. In children, especially those with asthma or other respiratory issues, parainfluenza can lead to more severe respiratory complications.

Pharmacokinetics

As viruses, parainfluenza do not have a pharmacokinetic profile like conventional drugs, since they replicate within host cells rather than being absorbed, distributed, metabolized, or excreted in the traditional sense. The duration of viral shedding can vary, with children typically shedding the virus for several days to weeks after infection. The immune response's effectiveness in clearing the virus is crucial in determining the duration of the infection and the recovery time.

Pregnancy

There is limited data on the safety of parainfluensis virus in pregnancy. Caution is advised when considering use during pregnancy.

Breast-feeding

There is limited data on the excretion of parainfluensis virus in human milk. Caution is advised when considering use while breastfeeding.

Storage

Store at a temperature of 2 to 8 degrees Celsius. Protect from light and moisture.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Indications

• Chronic hepatitis C infection
• Respiratory syncytial virus (RSV) infection
• Other viral infections as determined by a healthcare provider

Dosage

Children: Refer to established guidelines and local protocols for specific dosing recommendations.

Adults: Refer to established guidelines and local protocols for specific dosing recommendations.

Mechanism of action

Rabiei is a nucleoside analog that interferes with the replication of viral RNA. It is phosphorylated within the cell to its active form, ribavirin triphosphate, which inhibits the enzyme RNA-dependent RNA polymerase, thereby disrupting viral RNA synthesis. Additionally, it may also enhance the host's immune response to viral infections.

Pharmacodynamics

Rabiei exhibits broad-spectrum antiviral activity against various RNA viruses. Its efficacy is enhanced when used in combination therapy, as it can lead to synergistic effects with other antiviral agents. The drug's action results in a decrease in viral load and improved clinical outcomes in patients with chronic viral infections.

Pharmacokinetics

Rabiei is absorbed well after oral administration, with peak plasma concentrations occurring within one to two hours. It has a half-life of about 12 to 40 hours, depending on the formulation and patient factors. Rabiei is extensively distributed in body tissues and is metabolized primarily in the liver. It is eliminated through the kidneys, and renal impairment can significantly affect its clearance.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Therefore, the drug should be used during pregnancy only if clearly needed.

Breast-feeding

It is not known whether this drug is excreted in human milk. Caution should be exercised when administering to nursing women.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.